Seeking Alpha

More on Gilead Sciences (GILD): Q3 beats across the board. Net earnings fell 8.9% Y/Y however,...

More on Gilead Sciences (GILD): Q3 beats across the board. Net earnings fell 8.9% Y/Y however, on higher R&D expenses to advance its liver disease and oncolodgy products. Overall product sales rose 14%, with sales of antiviral products, its dominant revenue stream, increasing 13%. HIV drugs Atripla and Truvada both saw sales gains of 9% and 8%, respectively. Royalty, contract and other revenue from collaborations were up 23% from the prior year. Shares +1.7% AH.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs